Application | Comment | Organism |
---|---|---|
medicine | high expression of LEI in tumor cells may reduce the efficiency of etoposide as a chemotherapeutic agent. LEI inhibits cathepsin D, released from the lysosome during etoposide treatment. Cathepsin D enhances caspase activity in the cell by cleaving procaspase-8 and LEI overexpression slows down this cleavage, protecting cells from apoptosis | Sus scrofa |
Cloned (Comment) | Organism |
---|---|
wild-type or mutant LEI expressed in BHK-21 cells. 6xHis tagged wild-type and mutant LEI expressed from pET 23d(+) plasmid in Escherichia coli BL21(DE3)pLysS strain. Wild-type LEI expressed in HeLa cells | Sus scrofa |
Protein Variants | Comment | Organism |
---|---|---|
AP10T | point mutation in the hinge region of LEI, has decreased anti-protease activity. Cells overexpressing wild-type LEI or AP10T-LEI have the same survival rate under unstressed condition. Mutant retains its pro-apoptotic activity when transformed into L-DNase II by an apoptotic stimulus (e.g., hexa-methylene-amiloride treatment). When mutant cells are treated with etoposide they do not present the same survival rate than wild-type cells | Sus scrofa |
Localization | Comment | Organism | GeneOntology No. | Textmining |
---|---|---|---|---|
mitochondrion | fraction of procaspase-8 and LEI colocalise in the mitochondria. After etoposide treatment, cathepsin D is released from lysosomes and part of it colocalises with caspase-8 and LEI | Sus scrofa | 5739 | - |
Organism | UniProt | Comment | Textmining |
---|---|---|---|
Sus scrofa | - |
- |
- |
Synonyms | Comment | Organism |
---|---|---|
L-DNase II | - |
Sus scrofa |
LEI | - |
Sus scrofa |